BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05583227 (tezepelumab in eosinophilic esophagitis): BVCT ex-ante prediction vs. reported outcome

On 23 Aug 2026, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 20 Oct 2026 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient.

Clinical Trial

NCTID
NCT05583227
Acronym
CROSSING
Drug Name
tezepelumab
Drug MoA
anti-TSLP inhibitor
Drug Modality
monoclonal antibody
Drug Class
First-In-Class
Therapeutic Area
Immune System Diseases
Indication
eosinophilic esophagitis
Human Patients
368
Sponsor
Amgen/AstraZeneca
Phase
Phase 3

Prediction of , index 2178

Prospective Prediction
Prediction Index
2178
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient (additive) clinical benefit in DSQ non-superior-non-inferior to dupilumab with 0.9 < RR < 1.1)
Technical Prediction
SUCCESS (statistically significant (additive) clinical benefit in DSQ compare with placebo)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
58 days in advance
Readout Data Interpretation
tezepelumab 420mg achieved 22-point total DSQ improvement at week 24 which is numerically comparable with that of dupilumab (see add'l link below) and 7.3-point placebo-adjusted DSQ improvement (p<0.001)
Press Release
Additional Readout Data
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-11-04. Third-party data.

Official title
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients With Eosinophilic Esophagitis (CROSSING).
Phase
Phase 3
Status
Active not recruiting
Enrollment
368
Lead sponsor
AstraZeneca
Conditions
Eosinophilic Esophagitis
Interventions
BIOLOGICAL: Tezepelumab; BIOLOGICAL: Tezepelumab; OTHER: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2022-11-10
Primary completion
2026-07-14
Completion
2027-03-23
Primary outcomes
  • Histologic response of peak esophageal eosinophil per HPF count of ≤ 6 across all available esophageal levels (Week 24)
  • Change from baseline in DSQ (Dysphagia Symptom Questionnaire) score (Week 24)

NCT05583227 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials